Usage and dosage of Fizotinib: Precise dosing and dose adjustment

Fedratinib, trade name Inrebic, is an innovative medicine for the treatment of adult patients with intermediate or high-risk primary or secondary myelofibrosis (MF). It blocks the signaling pathways related to myelofibrosis by inhibiting the activity of Janus related kinase 2 (JAK2), thereby slowing or reversing the disease process. During the medication process, precise medication and reasonable dosage adjustment are crucial to ensure efficacy and reduce side effects.

The recommended dose of Fizotinib is 400 mg taken orally once daily. For most patients, this dose is effective in controlling the disease while maintaining good tolerability. Patients can choose to take it before or after meals, but it is recommended to take it at the same time every day to maintain a stable blood concentration and better exert its effect.

If a patient develops hematologic toxicities such as severe anemia, thrombocytopenia, or neutropenia, physicians may consider reducing the dose or suspending treatment until the toxicity resolves. For example, for patients with grade 3 or above anemia or who require blood transfusions, doctors will interrupt the dose of fizotinib until the hemoglobin level returns to a safe range and restart treatment at a lower dose.

For severe nausea, vomiting, diarrhea, liver enzyme elevation and other non-hematological toxicities, doctors will also consider reducing the dose or suspending treatment. After toxicity resolves, physicians will gradually increase the dose based on patient tolerance.

If patients concurrently use strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, etc.), the plasma concentration of fizotinib may be increased, thereby increasing the risk of adverse reactions. In this case, the doctor may reduce the dose of fezotinib to 200 mg and gradually increase the dose after stopping the CYP3A4 inhibitor.

During the period of using Fizotinib, patients need to undergo regular blood routine, liver function and other related tests so that doctors can monitor adverse drug reactions in a timely manner and adjust the treatment plan accordingly.

Reference materials:https://en.wikipedia.org/wiki/Fedratinib